CLINICAL TRIALS PROFILE FOR INLYTA
✉ Email this page to a colleague
All Clinical Trials for INLYTA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00700258 ↗ | Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] | Recruiting | Pfizer | 2008-01-04 | The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use | |
| NCT01321437 ↗ | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Completed | Pfizer | Phase 2 | 2011-12-01 | The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma. |
| NCT01321437 ↗ | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Completed | University of California, Irvine | Phase 2 | 2011-12-01 | The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma. |
| NCT01409200 ↗ | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | Active, not recruiting | National Cancer Institute (NCI) | Phase 2 | 2012-03-26 | This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph nodes. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as antiandrogen therapy may lessen the amount of androgen made by the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if antiandrogen therapy is more effective with or without axitinib before surgery in treating patients with prostate cancer. |
| NCT01409200 ↗ | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | Active, not recruiting | Pfizer | Phase 2 | 2012-03-26 | This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph nodes. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as antiandrogen therapy may lessen the amount of androgen made by the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if antiandrogen therapy is more effective with or without axitinib before surgery in treating patients with prostate cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for INLYTA
Condition Name
Clinical Trial Locations for INLYTA
Trials by Country
Clinical Trial Progress for INLYTA
Clinical Trial Phase
Clinical Trial Sponsors for INLYTA
Sponsor Name
